Bladder Instillation of Adriamycin in the Treatment of Bladder Cancer

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1983 Jan 1

PMID 6605814

Citations 1

Authors

C H Huang

C P Chiang

Affiliations

Soon will be listed here.

Abstract

Intravesical Adriamycin instillation was used in 10 patients with transitional cell carcinoma of the bladder as postoperative prophylactic treatment against recurrence. The protocol for bladder instillation was 20 mg/10 ml of Adriamycin twice weekly for a total of eight doses. One patient developed recurrence in 3 months and three, in 6 months. The main local side-effects were frequency and dysuria which occurred in four cases. Leukopenia and increased SGOT and SGPT values each occurred in one case. No cases of cardiotoxicity, fibrosis, or atrophy of the bladder mucosa were found. Further studies are necessary to achieve the best possible results.

Citing Articles

Attenuation effect of Abnormal Savda Munziq on liver and heart toxicity caused by chemotherapy in mice.

Aikemu A, Amat N, Yusup A, Shan L, Qi X, Upur H Exp Ther Med. 2016; 12(1):384-390.

PMID: 27347066 PMC: 4906975. DOI: 10.3892/etm.2016.3328.

References

LUTZEYER W, Rubben H, Dahm H . Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol. 1982; 127(2):250-2. DOI: 10.1016/s0022-5347(17)53725-8. View

MELICOW M . Tumors of the bladder: a multifaceted problem. J Urol. 1974; 112(4):467-78. DOI: 10.1016/s0022-5347(17)59764-5. View

Soloway M . Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J Urol. 1980; 123(4):461-6. DOI: 10.1016/s0022-5347(17)55976-5. View

Soloway M, MURPHY W, DeFuria M, Crooke S, Finebaum P . The effect of mitomycin C on superficial bladder cancer. J Urol. 1981; 125(5):646-8. DOI: 10.1016/s0022-5347(17)55149-6. View

Morales A, Ottenhof P, Emerson L . Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin. J Urol. 1981; 125(5):649-51. DOI: 10.1016/s0022-5347(17)55150-2. View

Catalona W, Chretien P . Correlation among host immunocompetence and tumor stage, tumor grade and vascular permeation in transitional carcinoma. J Urol. 1973; 110(5):526-8. DOI: 10.1016/s0022-5347(17)60270-2. View

Amin M, LICH Jr R . Lymphocytes and bladder cancer. J Urol. 1974; 111(2):165-9. DOI: 10.1016/s0022-5347(17)59917-6. View

Loening S, Narayana A, Yoder L, Slymen D, Weinstein S, Penick G . Factors influencing the recurrence rate of bladder cancer. J Urol. 1980; 123(1):29-31. DOI: 10.1016/s0022-5347(17)55763-8. View

Ozaki Y . [Bladder instillation of adriamycin in the treatment of bladder tumors. Report 1: Clinical results (author's transl)]. Nihon Hinyokika Gakkai Zasshi. 1977; 68(10):934-44. DOI: 10.5980/jpnjurol1928.68.10_934. View

10.

Mitchell R . Intravesical thiotepa in the treatment of transitional cell bladder carcinoma. Br J Urol. 1971; 43(2):185-8. DOI: 10.1111/j.1464-410x.1971.tb12024.x. View

11.

Greene L, Hanash K, Farrow G . Benign papilloma or papillary carcinoma of the bladder?. J Urol. 1973; 110(2):205-7. DOI: 10.1016/s0022-5347(17)60161-7. View

12.

Catalona W, Tarpley J, Chretien P, Castle J . Lymphocyte stimulation in urologic cancer patients. J Urol. 1974; 112(3):373-7. DOI: 10.1016/s0022-5347(17)59734-7. View

13.

Banks M, Pontes J, Izbicki R, PIERCE Jr J . Topical instillation of doxorubicin hydrochloride in the treatment of recurring superficial transitional cell carcinoma of the bladder. J Urol. 1977; 118(5):757-60. DOI: 10.1016/s0022-5347(17)58182-3. View

14.

Jacobi G, Kurth K . Studies on the intravesical action of topically administered G3H-doxorubicin hydrochloride in men: plasma uptake and tumor penetration. J Urol. 1980; 124(1):34-7. DOI: 10.1016/s0022-5347(17)55279-9. View

15.

McLaughlin 3rd A, Kessler W, Triman K, Gittes R . Immunologic competence in patients with urologic cancer. J Urol. 1974; 111(2):233-7. DOI: 10.1016/s0022-5347(17)59936-x. View

16.

Robinson M, Shetty M, Richards B, Bastable J, GLASHAN R, Smith P . Intravesical epodyl in the management of bladder tumors: combined experience of the Yorkshire Urological Cancer Research Group. J Urol. 1977; 118(6):972-3. DOI: 10.1016/s0022-5347(17)58267-1. View

17.

RIDDLE P, Wallace D . Intracavitary chemotherapy for multiple non-invasive bladder tumours. Br J Urol. 1971; 43(2):181-4. DOI: 10.1111/j.1464-410x.1971.tb12023.x. View

18.

Jakse G, Hofstadter F, MARBERGER H . Intracavitary doxorubicin hydrochloride therapy for carcinoma in situ of the bladder. J Urol. 1981; 125(2):185-90. DOI: 10.1016/s0022-5347(17)54959-9. View

19.

Mishina T, Oda K, Murata S, Ooe H, Mori Y . Mitomycin C bladder instillation therapy for bladder tumors. J Urol. 1975; 114(2):217-9. DOI: 10.1016/s0022-5347(17)66989-1. View

20.

Koontz Jr W, Prout Jr G, Smith W, Frable W, Minnis J . The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder. J Urol. 1981; 125(3):307-12. DOI: 10.1016/s0022-5347(17)55018-1. View